Page 18 - 《中国药房》2024年3期

15（14）：1979-1989. of imatinib in patients with gastrointestinal stromal tumors
[33] DEMETRI G D，VAN OOSTEROM A T，GARRETT C [J]. Drug Metab Pharmacokinet，2022，43：100441.
R，et al. Efficacy and safety of sunitinib in patients with [43] MA G L，MURPHY J D，MARTINEZ M E，et al. Epide‐
advanced gastrointestinal stromal tumour after failure of miology of gastrointestinal stromal tumors in the era of
imatinib：a randomised controlled trial[J]. Lancet，2006， histology codes：results of a population-based study[J].
368（9544）：1329-1338. Cancer Epidemiol Biomarkers Prev，2015，24（1）：
[34] DEMETRI G D，REICHARDT P，KANG Y K，et al. Effi‐ 298-302.
cacy and safety of regorafenib for advanced gastrointesti‐ [44] XU H，LIU Q. Individualized management of blood con‐
nal stromal tumours after failure of imatinib and sunitinib centration in patients with gastrointestinal stromal tumors
（GRID） ：an international，multicentre，randomised， [J]. Onco Targets Ther，2020，13：13345-13355.
placebo-controlled，phase 3 trial[J]. Lancet，2013，381 [45] JUDSON I，MA P M，PENG B，et al. Imatinib pharmaco‐
（9863）：295-302. kinetics in patients with gastrointestinal stromal tumour：a
[35] RAUT C P，ESPAT N J，MAKI R G，et al. Efficacy and retrospective population pharmacokinetic study over time：
tolerability of 5-year adjuvant imatinib treatment for pa‐ EORTC soft tissue and bone sarcoma group[J]. Cancer
tients with resected intermediate- or high-risk primary ga- Chemother Pharmacol，2005，55（4）：379-386.
strointestinal stromal tumor：the PERSIST-5 clinical trial [46] WU X Y，LI J，ZHOU Y，et al. Relative factors analysis of
[J]. JAMA Oncol，2018，4（12）：e184060. imatinib trough concentration in Chinese patients with ga-
[36] VAN GLABBEKE M，VERWEIJ J，CASALI P G，et al. strointestinal stromal tumor[J]. Chemotherapy，2018，63
Predicting toxicities for patients with advanced gastroin‐ （6）：301-307.
testinal stromal tumours treated with imatinib：a study of [47] HOUK B E，BELLO C L，KANG D，et al. A population
the European Organisation for Research and Treatment of pharmacokinetic meta-analysis of sunitinib malate
Cancer，the Italian Sarcoma Group，and the Australasian （SU11248） and its primary metabolite （SU12662） in
Gastro-Intestinal Trials Group （EORTC-ISG-AGITG）[J]. healthy volunteers and oncology patients[J]. Clin Cancer
Eur J Cancer，2006，42（14）：2277-2285. Res，2009，15（7）：2497-2506.
[37] YIN Y，XIANG J，TANG S M，et al. A lower dosage of [48] 张鹏，韩勇，周红，等. 中国胃肠间质瘤患者服用伊马替
imatinib in patients with gastrointestinal stromal tumors 尼稳态谷浓度的初步分析[J]. 中国医院药学杂志，2016，
with toxicity of the treatment[J]. Medicine，2016，95（49）： 36（20）：1787-1790.
e5488. ZHANG P，HAN Y，ZHOU H，et al. Distribution of ima‐
[38] LIU J，CHEN Z Y，CHEN H M，et al. Genetic polymor‐ tinib trough concentration at steady state in Chinese pa‐
phisms contribute to the individual variations of imatinib tients with gastrointestinal stromal tumor[J]. Chin J Hosp
mesylate plasma levels and adverse reactions in Chinese Pharm，2016，36（20）：1787-1790.
GIST patients[J]. Int J Mol Sci，2017，18（3）：603. [49] CLARKE W A，CHATELUT E，FOTOOHI A K，et al.
[39] WIDMER N，DECOSTERD L A，CSAJKA C，et al. Popu‐ Therapeutic drug monitoring in oncology：international
lation pharmacokinetics of imatinib and the role of alpha- association of therapeutic drug monitoring and clinical
acid glycoprotein[J]. Br J Clin Pharmacol，2006，62（1）： toxicology consensus guidelines for imatinib therapy[J].
97-112. Eur J Cancer，2021，157：428-440.
[40] HARIVENKATESH N，KUMAR L，BAKHSHI S，et al. [50] BOUCHET S，POULETTE S，TITIER K，et al. Relation‐
Influence of MDR1 and CYP3A5 genetic polymorphisms ship between imatinib trough concentration and outcomes
on trough levels and therapeutic response of imatinib in in the treatment of advanced gastrointestinal stromal tu‐
newly diagnosed patients with chronic myeloid leukemia mours in a real-life setting[J]. Eur J Cancer，2016，57：
[J]. Pharmacol Res，2017，120：138-145. 31-38.
[41] YAMAKAWA Y，HAMADA A，NAKASHIMA R，et al. [51] WANG Y R，ZHANG P，HAN Y，et al. Adherence to adju‐
Association of genetic polymorphisms in the influx tran- vant imatinib therapy in patients with gastrointestinal stro‐
sporter SLCO1B3 and the efflux transporter ABCB1 with mal tumor in clinical practice：a cross-sectional study[J].
imatinib pharmacokinetics in patients with chronic myeloid Chemotherapy，2019，64（4）：197-204.
leukemia[J]. Ther Drug Monit，2011，33（2）：244-250. [52] LANKHEET N A G，DESAR I M E，MULDER S F，et al.
[42] MAEKAWA K，YAMAMURA M，MATSUKI A，et al. Im‐ Optimizing the dose in cancer patients treated with ima‐
pacts of SNPs on adverse events and trough concentration tinib，sunitinib and pazopanib[J]. Br J Clin Pharmacol，

· 268 · China Pharmacy 2024 Vol. 35 No. 3 中国药房 2024年第35卷第3期